MAX and prostate cancer: In support of c-MYC mediating resistance to ARSI treatment, Bai et al. recently showed that a c-Myc inhibitor disrupting c-Myc and Max dimerization sensitizes enzalutamide-resistant prostate cancer cells to growth inhibition by enzalutamide53.